A comparison of efficacy between recombinant activated factor VII (ARYOSEVEN TM) and NOVOSEVEN® in patients with hereditary FVIII deficiency with inhibitor

Pediatric Hematology and Oncology, Iranian Blood Transfusion Organization, Tehran, Iran; Pediatric Hematology and Oncology, Mofid Children's Hospital, Tehran, Iran; Adult Hematology and Oncology, Tehran University of medical sciences, Tehran, Iran; Pediatric Hematology and Oncology, Shadid Beheshti University, Tehran, Iran; Shahid Beheshti University of Medical Science, Tehran, Iran; General Practitioner, Isfan University, Tehran, Iran; Eums, Thalassemia, Iran; Oncology, AUMS, Tehran, Iran; Aryogen Zist Darou, Tehran, Italy; Epidemiology, Tehran University, Tehran, Iran; Research, Aryogen Zist Darou, Tehran, Iran; Chronic Diseases Research center, Tehran University of medical sciences, Tehran, Iran; Hemophilia, CHCC, Tehran, Iran; Pediatric Hematology and Oncology, Golestan University, Tehran, Iran; General Practitioner, Kerman University, Tehran, Iran; Zahedan Medical University, Zahedan, Iran; Hematology, IBTO, Tehran, Iran; Biotechnology, Aryogen Zist Darou, Tehran, Iran

Blood. 2014;124((21)): Abstract No. 4299
Study details